We’ve issued final draft guidance recommending a new once-a-day tablet that is set to benefit around 1,100 people with a type ...

NICE is proposing changes to its routing criteria for Highly Specialised Technologies (HST) to ensure more consistent, ...

Anhydrous sodium thiosulfate, also known as Pedmarqsi and made by Norgine, is recommended in final draft guidance for preventing hearing loss caused by cisplatin chemotherapy in children from the ages ...

Tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults, only if they have: an initial body mass index ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...

This guidance represents the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, healthcare professionals are expected to take this ...

If you’re commenting for an organisation, your organisation needs to be registered as a stakeholder. We can accept comments from individuals. These will be considered, but you won’t get a formal ...

NICE inherited the 7 highly specialised technologies (HST) routing criteria from AGNSS (Advisory Group for National Specialised Services) in 2013. Following that, the NICE Highly Specialised ...

NICE has produced a resource impact assessment tool for tirzepatide. NICE estimates that the total eligible population is 3.4 million people, and expects that an interim NHS England commissioning ...

A list of downloadable documents created during development.

There is a simple discount patient access scheme for ublituximab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...